CHANGES IN THE RBC PROTEOME DURING HEALTH AND DISEASE

健康和疾病期间红细胞蛋白质组的变化

• 批准号: 8143519
• 负责人: Monica Bessler
• 金额: $ 33.76万
• 依托单位: CHILDREN'S HOSP OF PHILADELPHIA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-15 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8143519
• 关键词: Acquired Hemolytic Anemia; Age; Bioinformatics; Biological; Biological Markers; Cancer Center; Cataloging; Catalogs; Cell membrane; Collaborations; Complement; Complement component C5; Complex Mixtures; Computer Analysis; Computer software; Core Facility; Coupled; Cyclotrons; Cytolysis; Data; Detection; Development; Diagnosis; Diagnostic tests; Diamond-Blackfan anemia; Disease; Dose; Erythrocytes; Erythroid; Erythroid Cells; Female; Fourier Transform; Functional disorder; Gender; Goals; Grant; Health; Individual; Individual Differences; Inherited; Investigation; Ions; Label; Lead; Life; Maintenance; Mass Spectrum Analysis; Measures; Mediating; Membrane; Methods; Modeling; Molecular; Molecular Profiling; Monitor; NIH Program Announcements; National Institute of Diabetes and Digestive and Kidney Diseases; Outcome; Patients; Pattern; Peptides; Pharmaceutical Preparations; Physiological; Preparation; Proteins; Proteome; Proteomics; Race; Research; Risk; Running; Sampling; Sex Characteristics; Steroids; Testing; Time; Universities; Variant; Washington; abstracting; capillary liquid chromatography; comparative; computerized data processing; density; inhibitor/antagonist; insight; instrument; male; mass spectrometer; nano; novel; novel marker; outcome forecast; protein expression; public health relevance; rat Piga protein; response; tool

DESCRIPTION (provided by applicant): "Changes in the RBC proteome during health and disease" Abstract: Recent studies of the red blood cell (RBC) proteome have yielded extensive lists of both membrane and soluble proteins. While these catalogs of RBC proteins are quite impressive, they contain little if any quantitative information. The analysis of differential protein expression can be crucial for the discovery and understanding of the biological underpinnings of disease, as well as for providing novel biomarkers for diagnosis or prognosis, for assessing risk profiles and outcomes, and for identifying novel targets for individualized treatment. Within the last few years there have been significant advances in mass spectrometry and software for the quantitative, comparative analysis of complex mixtures of peptides. We hypothesize that the global quantitative expression patterns of proteins in RBC will reflect differences that exist in normal live but also those that occur due to disease. Here we propose to develop a robust, label-free proteomics platform for defining differential protein expression in RBCs. We will assess the level of technical variation, as well as define variations due to inter-individual and gender differences. We will then test the platform developed and apply it to define the differences in global protein expression patterns in two classic red blood cell disorders, Paroxysmal Nocturnal Hemoglobinuria (PNH) and Diamond Blackfan Anemia (DBA). Finally, we will use the platform developed and the signature proteins that define the disease to monitor the changes that occur in the RBC proteome during disease specific treatment. Our findings are likely to provide new insights into the pathophysiology of these diseases, and might lead to the identification of novel markers, or to the discovery of new targets for the development of diagnostic tests or drugs. Furthermore, the tools we develop should prove broadly applicable to the quantitative comparison of RBC membrane proteomes of varying physiological or disease states. PUBLIC HEALTH RELEVANCE: We hypothesize that the global quantitative expression patterns of red cell proteins will reflect normal physiological variations, as well as variations that occur during disease. In this grant we propose to develop a robust, label-free proteomics platform for defining differential protein expression in red blood cells. We will assess the level of technical variation associated with the platform and define variations due to normal physiological differences. We will then test the developed platform by applying it to define the differences in global protein expression patterns that occur in two classic red blood cell disorders, namely Paroxysmal Nocturnal Hemoglobinuria (PNH) and Diamond Blackfan Anemia (DBA). Our investigations are likely to provide new insights into the pathophysiology of these diseases, and might lead to the identification of novel markers, or to the discovery of new targets for the development of diagnostic tests or drugs. Furthermore, the platform we develop should prove broadly applicable to the quantitative comparison of RBC proteomes of varying physiological or disease states.

描述(申请人提供)：“RBC蛋白质组在健康和疾病过程中的变化”摘要：最近对红细胞蛋白质组的研究已经产生了广泛的膜和可溶性蛋白质清单。虽然这些RBC蛋白质目录令人印象深刻，但它们包含的定量信息很少。对差异蛋白表达的分析对于发现和了解疾病的生物学基础，以及为诊断或预后提供新的生物标志物，评估风险概况和结果，以及确定个性化治疗的新靶点，都是至关重要的。在过去的几年里，在用于对复杂的多肽混合物进行定量、比较分析的质谱学和软件方面取得了重大进展。我们假设，RBC中蛋白质的全球定量表达模式将反映正常生活中存在的差异，也反映那些因疾病而发生的差异。在这里，我们建议开发一个健壮的、无标记的蛋白质组学平台，用于定义红细胞中的差异蛋白质表达。我们将评估技术差异的水平，并定义由于个人和性别差异造成的差异。然后，我们将测试开发的平台，并应用它来确定两种经典红细胞疾病-阵发性睡眠性血红蛋白尿症(PNH)和钻石黑扇贫血(DBA)-全球蛋白质表达模式的差异。最后，我们将使用开发的平台和定义疾病的标志性蛋白质来监测疾病特异性治疗期间红细胞蛋白质组发生的变化。我们的发现可能为这些疾病的病理生理学提供新的见解，并可能导致识别新的标记物，或发现新的诊断测试或药物开发的靶点。此外，我们开发的工具应该被证明广泛适用于不同生理或疾病状态的红细胞膜蛋白质组的定量比较。 与公共卫生相关：我们假设，红细胞蛋白的全球数量表达模式将反映正常的生理变化，以及疾病期间发生的变化。在这笔赠款中，我们建议开发一个强大的、无标记的蛋白质组学平台，用于定义红细胞中差异蛋白质的表达。我们将评估与平台相关的技术差异水平，并定义由于正常生理差异而产生的差异。然后，我们将测试开发的平台，应用它来确定两种经典红细胞疾病，即阵发性睡眠性血红蛋白尿症(PNH)和钻石黑扇贫血(DBA)中出现的全球蛋白质表达模式的差异。我们的研究可能为这些疾病的病理生理学提供新的见解，并可能导致识别新的标记物，或为诊断测试或药物的开发发现新的靶点。此外，我们开发的平台应该被证明广泛适用于不同生理或疾病状态的RBC蛋白质组的定量比较。